Calimmune raises $15M in Series B

What does Calimmune do?

Calimmune, is a clinical stage gene therapy company. Its lead therapeutic candidate, is a gene based therapy which is engineered to control HIV infection and for protecting individuals with HIV from advancing to AIDS. The therapy is presently being evaluated in Phase I/II studies. Cal- 1 is designed for reducing production of CCR5, which is a protein present on the surface of WBC which plays an important role in enabling HIV to infect cells. It also has a 2^nd mechanis, which is aimed to prevent viral infusion, the process by which the virus enters into the cell. This approach is being effective against broad strains of HIV in pre-clinical studies.

How much Calimmune was funded?

Calimmune raised $15M in Series B funding on May 27, 2015 from RA Capital Healthcare, Alexandria Venture and Translational Accelerator.

What is next for Calimmune?

The funding raised will be used to progress the company’s ongoing clinical trails on HIV/AIDS and for its advanced technology research programs and general corporate operations.

More about Calimmune?

Calimmune was founded in 2006 and has its headquarters in Tuscon, Arizona. It is developed from technology developed in the labs of Nobel Laureate David Baltimore, Ph.D, Inder M.Verma, Ph.D, Irvin Chen, Ph.D. This company is engineering immunity. It is a clinical stage biotech company which develops novel gene therapies which have the potential of improving and protecting the lives of patients by improving their immune systems. Its initial disease target is HIV/AIDS.

The company’s lead therapeutic candidate, Cal- 1, is a gene based therapy which is engineered to control HIV infection and to protect people with HIV from progressing to AIDS. It is currently being evaluated in Phase I/II studies. It is designed for reducing production of CCR5. It also prevents viral infusion, the process by which virus enters the cell.